Phathom Pharmaceuticals Inc (PHAT)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Phathom Pharmaceuticals Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 6 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 169.3% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -1.05 | – | 30 | 4,249.60 | -251.00 | -64 | -64 |
| 2025: Q1 | -1.31 | – | 29 | 1,391.60 | -330.70 | -85 | -85 |
| 2025: Q2 | -1.05 | – | 40 | 439.40 | -191.90 | -63 | -63 |
| 2025: Q3 | -0.41 | – | 50 | 202.70 | -60.50 | -14 | -14 |
| 2025: Q4 | -0.29 | – | 58 | 94.10 | -36.70 | -5 | -5 |
| 2026: Q1 | -0.37 | – | 58 | 104.40 | -52.10 | -16 | -16 |
| 2026: Q2 | -0.21 | 80.00 | 74 | 88.10 | -23.70 | -2 | -2 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Phathom Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States.
| Employees | 371 |
|---|---|
| Headquarters | Florham Park, NJ |
| Website | phathompharma.com |
| IPO Date | 25. Oct 2019 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Steven L. Basta M.B.A. | CEO, President & Director | 1966 |
| David A. Socks | Co-Founder | 1975 |
| Azmi Nabulsi M.D., M.P.H. | Co-Founder | 1960 |
| Sanjeev Narula | Chief Financial & Business Officer | 1962 |
| Anne Marie Cook Esq., J.D. | Chief Legal Officer & Corporate Secretary | 1962 |
| Jonathan Bentley | Senior VP and Head of Sales, Operations & Training | – |
| Robert Breedlove | VP of Finance & Principal Accounting Officer | – |
| Eric Sciorilli | Director of Business Development & Investor Relations | – |
| Bill Aprea J.D. | Senior VP, Chief Compliance Officer & Deputy Chief Legal Officer | – |
| Nancy R. Phelan | Senior Vice President of Marketing & Analytics | 1969 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 14. Jul 2026 | Breedlove Robert Charles | Principal Accounting Officer | Other | 1,555 | 11.04 | 17,159 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.